Virologic 100 % Chance ? - 500 Beiträge pro Seite
eröffnet am 08.03.02 15:56:45 von
neuester Beitrag 29.09.02 10:32:46 von
neuester Beitrag 29.09.02 10:32:46 von
Beiträge: 48
ID: 562.978
ID: 562.978
Aufrufe heute: 0
Gesamt: 4.152
Gesamt: 4.152
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 14 Minuten | 1993 | |
| gestern 12:15 | 1101 | |
| vor 16 Minuten | 893 | |
| vor 17 Minuten | 890 | |
| vor 15 Minuten | 739 | |
| vor 47 Minuten | 716 | |
| gestern 19:30 | 625 | |
| heute 05:38 | 580 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.062,16 | -0,14 | 200 | |||
| 2. | 2. | 9,7000 | +0,57 | 184 | |||
| 3. | 3. | 149,32 | -1,48 | 132 | |||
| 4. | 4. | 0,1905 | -1,80 | 70 | |||
| 5. | 6. | 0,0211 | -32,59 | 29 | |||
| 6. | 5. | 6,7020 | -0,62 | 29 | |||
| 7. | 7. | 1,3400 | -0,74 | 29 | |||
| 8. | 15. | 2,3300 | -1,10 | 26 |
Feedback
Das USA Biotechunternehmen dürfte vor einer Rally stehen. Eure Meinung ?
300%, mindestens. KAUFEN, ALLES!!! Nach oben immer, runter nimmer!
Hallo Hubi,
was ist denn nun mit den 100%? Ich habe 10T da drin. Irgendwelche Neuigkeiten?
Horst
was ist denn nun mit den 100%? Ich habe 10T da drin. Irgendwelche Neuigkeiten?
Horst
--------------------------------------------------------------------------------
ViroLogic Raises $10 Million Through Private Placement Cash Position Sufficient to Achieve Breakeven by the End of 2002
SOUTH SAN FRANCISCO, Calif., Mar 26, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today announced it has closed a transaction to
sell newly designated shares of 6% convertible preferred stock to several large
investors in a private placement resulting in gross proceeds to the company of
$10 million.
ViroLogic expects to use the proceeds from this financing to support and enhance
ongoing commercial activities, accelerate research and development of new
products, and for general administrative expenses, capital expenditures and
working capital.
"The Company`s cash position should now be sufficient to get us to breakeven by
the end of 2002," said Bill Young, ViroLogic`s Chairman and CEO. "It comes at a
great time as we continue to increase sales, launch new products and turn the
corner to profitability."
ViroLogic develops and markets rapid, highly sensitive drug resistance assays
that allow physicians to directly and reliably measure the level of clinically
significant HIV drug resistance. With this information, physicians can
individualize treatment regimens for their patients to maintain effective
therapy and avoid unnecessary side effects, resulting in improved outcomes and
reduced treatment costs. Pharmaceutical companies are also using ViroLogic`s
assays to develop new drugs to which HIV might be less resistant. ViroLogic is
the only company to directly market a full line of premium resistance
technologies, including phenotyping, genotyping and the combination of the two.
In addition, ViroLogic has a robust pipeline of new products which it plans to
launch throughout the year, including a patient testing assay for viral fitness
and drug development assays for HIV vaccines and hepatitis B virus.
The preferred stock will be convertible into common stock at a premium to the
current market price. The purchasers will also receive warrants to purchase a
total of 2.2 million shares of common stock, at an exercise price that is also
at a premium to the current market price. The offer and sale of the securities
being sold by ViroLogic in the private placement will not be and has not been
registered under the Securities Act of 1933, as amended, and may not be sold by
ViroLogic absent registration or an applicable exemption from registration
requirements. However, the Company has agreed to file a registration statement
for the resale of the shares underlying the preferred stock and the warrants.
This news release is not an offer to sell, or a solicitation of an offer to buy,
the securities discussed herein.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine and
pharmacogenomics by discovering, developing and marketing innovative products to
guide and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company`s products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company`s technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines
targeted at emerging drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the offer and sale of shares of preferred stock and the
issuance of warrants, the potential of the Company to reach breakeven and become
profitable, as well as anticipated uses of proceeds and potential pipeline and
product development efforts. These forward-looking statements are subject to
risks and uncertainties and other factors, which may cause actual results to
differ materially from the anticipated results or other expectations expressed
in such forward-looking statements. These risks and uncertainties include, but
are not limited to, whether planned pipeline and product development efforts
will be successful, whether PhenoSense(TM) testing will achieve market
acceptance, whether payers will authorize reimbursement for our products,
whether we will be able to expand our sales and marketing capabilities, whether
we encounter problems or delays in automating our process, whether we
successfully introduce new products using our PhenoSense technology, including
entry, fitness, vaccine and hepatitis assays, whether intellectual property
underlying our PhenoSense technology is adequate, whether we are able to build
brand loyalty, the ability to raise additional capital, and other risks and
uncertainties detailed from time to time in our reports to the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the year ended
December 31, 2000 and the Company`s most recent Report on Form 10-Q.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X88568023
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
URL: http://www.virologic.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
ViroLogic Raises $10 Million Through Private Placement Cash Position Sufficient to Achieve Breakeven by the End of 2002
SOUTH SAN FRANCISCO, Calif., Mar 26, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today announced it has closed a transaction to
sell newly designated shares of 6% convertible preferred stock to several large
investors in a private placement resulting in gross proceeds to the company of
$10 million.
ViroLogic expects to use the proceeds from this financing to support and enhance
ongoing commercial activities, accelerate research and development of new
products, and for general administrative expenses, capital expenditures and
working capital.
"The Company`s cash position should now be sufficient to get us to breakeven by
the end of 2002," said Bill Young, ViroLogic`s Chairman and CEO. "It comes at a
great time as we continue to increase sales, launch new products and turn the
corner to profitability."
ViroLogic develops and markets rapid, highly sensitive drug resistance assays
that allow physicians to directly and reliably measure the level of clinically
significant HIV drug resistance. With this information, physicians can
individualize treatment regimens for their patients to maintain effective
therapy and avoid unnecessary side effects, resulting in improved outcomes and
reduced treatment costs. Pharmaceutical companies are also using ViroLogic`s
assays to develop new drugs to which HIV might be less resistant. ViroLogic is
the only company to directly market a full line of premium resistance
technologies, including phenotyping, genotyping and the combination of the two.
In addition, ViroLogic has a robust pipeline of new products which it plans to
launch throughout the year, including a patient testing assay for viral fitness
and drug development assays for HIV vaccines and hepatitis B virus.
The preferred stock will be convertible into common stock at a premium to the
current market price. The purchasers will also receive warrants to purchase a
total of 2.2 million shares of common stock, at an exercise price that is also
at a premium to the current market price. The offer and sale of the securities
being sold by ViroLogic in the private placement will not be and has not been
registered under the Securities Act of 1933, as amended, and may not be sold by
ViroLogic absent registration or an applicable exemption from registration
requirements. However, the Company has agreed to file a registration statement
for the resale of the shares underlying the preferred stock and the warrants.
This news release is not an offer to sell, or a solicitation of an offer to buy,
the securities discussed herein.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine and
pharmacogenomics by discovering, developing and marketing innovative products to
guide and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company`s products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company`s technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines
targeted at emerging drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the offer and sale of shares of preferred stock and the
issuance of warrants, the potential of the Company to reach breakeven and become
profitable, as well as anticipated uses of proceeds and potential pipeline and
product development efforts. These forward-looking statements are subject to
risks and uncertainties and other factors, which may cause actual results to
differ materially from the anticipated results or other expectations expressed
in such forward-looking statements. These risks and uncertainties include, but
are not limited to, whether planned pipeline and product development efforts
will be successful, whether PhenoSense(TM) testing will achieve market
acceptance, whether payers will authorize reimbursement for our products,
whether we will be able to expand our sales and marketing capabilities, whether
we encounter problems or delays in automating our process, whether we
successfully introduce new products using our PhenoSense technology, including
entry, fitness, vaccine and hepatitis assays, whether intellectual property
underlying our PhenoSense technology is adequate, whether we are able to build
brand loyalty, the ability to raise additional capital, and other risks and
uncertainties detailed from time to time in our reports to the Securities and
Exchange Commission, including our Annual Report on Form 10-K for the year ended
December 31, 2000 and the Company`s most recent Report on Form 10-Q.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X88568023
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
URL: http://www.virologic.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Heute gute Umsätze,geht da bald was?
Trading Spotlight
100%? - 1000% meiner Meinung nach.
Hallo und guten Abend
bin auch noch mit dabei und muß schon sagen die Umsätze sind erheblich
Intraday PricesDate Time High Low Close Volume
04/10/02 13:45:53 2.340 2.340 2.340 17,000
04/10/02 13:41:51 2.350 2.350 2.350 22,000
04/10/02 13:41:19 2.370 2.350 2.370 16,600
04/10/02 13:41:59 2.350 2.350 2.350 9,300
04/10/02 13:40:45 2.350 2.350 2.350 10,000
04/10/02 13:39:15 2.350 2.350 2.350 2,300
04/10/02 12:05:53 2.350 2.350 2.350 2,000
04/10/02 12:05:42 2.349 2.349 2.349 500
04/10/02 12:02:09 2.340 2.340 2.340 100
04/10/02 11:16:55 2.360 2.360 2.360 5,000
04/10/02 11:10:13 2.370 2.340 2.340 26,000
04/10/02 11:08:28 2.359 2.350 2.350 4,600
04/10/02 11:03:52 2.350 2.350 2.350 5,200
04/10/02 10:57:59 2.370 2.360 2.370 1,000
04/10/02 10:51:45 2.360 2.360 2.360 200
04/10/02 10:48:43 2.370 2.370 2.370 100
04/10/02 10:45:06 2.360 2.360 2.360 1,400
04/10/02 10:25:33 2.390 2.360 2.360 1,000
04/10/02 10:25:10 2.400 2.390 2.400 5,000
04/10/02 10:14:43 2.384 2.384 2.384 100
04/10/02 10:03:45 2.400 2.400 2.400 4,500
04/10/02 10:02:43 2.400 2.399 2.400 2,500
04/10/02 09:57:24 2.400 2.390 2.400 9,500
04/10/02 09:55:08 2.390 2.390 2.390 500
04/10/02 09:45:05 2.399 2.399 2.399 1,000
04/10/02 09:43:56 2.400 2.400 2.400 33,900
04/10/02 09:39:53 2.390 2.390 2.390 200
04/10/02 09:38:45 2.400 2.400 2.400 6,400
04/10/02 09:34:35 2.400 2.400 2.400 15,000
04/10/02 09:34:14 2.390 2.380 2.380 18,900
04/10/02 09:32:00 2.400 2.390 2.400 20,400
04/10/02 09:31:13 2.390 2.390 2.390 14,600
04/10/02 09:31:57 2.390 2.390 2.390 5,000
04/10/02 09:29:22 2.390 2.390 2.390 500
04/10/02 09:15:38 2.390 2.380 2.390 2,500
04/10/02 09:05:49 2.390 2.390 2.390 700
04/10/02 09:03:51 2.390 2.390 2.390 2,800
04/10/02 09:02:27 2.390 2.390 2.390 1,000
04/10/02 09:01:03 2.390 2.390 2.390 2,900
04/10/02 08:58:12 2.390 2.390 2.390 1,800
Im Vergleich zu den Umsätzen vorher!
Ihr müßt mal auf die Seite www.investtech.com gehen.Schaut Euch mal die Kurzanalyse an.Die ist schon etwas besser geworden.(den Chart bekomme ich einfach nicht reinkopiert.wer es kann bitte mir verraten
Bis denne auf steigende Kurse Donkosak
bin auch noch mit dabei und muß schon sagen die Umsätze sind erheblich
Intraday PricesDate Time High Low Close Volume
04/10/02 13:45:53 2.340 2.340 2.340 17,000
04/10/02 13:41:51 2.350 2.350 2.350 22,000
04/10/02 13:41:19 2.370 2.350 2.370 16,600
04/10/02 13:41:59 2.350 2.350 2.350 9,300
04/10/02 13:40:45 2.350 2.350 2.350 10,000
04/10/02 13:39:15 2.350 2.350 2.350 2,300
04/10/02 12:05:53 2.350 2.350 2.350 2,000
04/10/02 12:05:42 2.349 2.349 2.349 500
04/10/02 12:02:09 2.340 2.340 2.340 100
04/10/02 11:16:55 2.360 2.360 2.360 5,000
04/10/02 11:10:13 2.370 2.340 2.340 26,000
04/10/02 11:08:28 2.359 2.350 2.350 4,600
04/10/02 11:03:52 2.350 2.350 2.350 5,200
04/10/02 10:57:59 2.370 2.360 2.370 1,000
04/10/02 10:51:45 2.360 2.360 2.360 200
04/10/02 10:48:43 2.370 2.370 2.370 100
04/10/02 10:45:06 2.360 2.360 2.360 1,400
04/10/02 10:25:33 2.390 2.360 2.360 1,000
04/10/02 10:25:10 2.400 2.390 2.400 5,000
04/10/02 10:14:43 2.384 2.384 2.384 100
04/10/02 10:03:45 2.400 2.400 2.400 4,500
04/10/02 10:02:43 2.400 2.399 2.400 2,500
04/10/02 09:57:24 2.400 2.390 2.400 9,500
04/10/02 09:55:08 2.390 2.390 2.390 500
04/10/02 09:45:05 2.399 2.399 2.399 1,000
04/10/02 09:43:56 2.400 2.400 2.400 33,900
04/10/02 09:39:53 2.390 2.390 2.390 200
04/10/02 09:38:45 2.400 2.400 2.400 6,400
04/10/02 09:34:35 2.400 2.400 2.400 15,000
04/10/02 09:34:14 2.390 2.380 2.380 18,900
04/10/02 09:32:00 2.400 2.390 2.400 20,400
04/10/02 09:31:13 2.390 2.390 2.390 14,600
04/10/02 09:31:57 2.390 2.390 2.390 5,000
04/10/02 09:29:22 2.390 2.390 2.390 500
04/10/02 09:15:38 2.390 2.380 2.390 2,500
04/10/02 09:05:49 2.390 2.390 2.390 700
04/10/02 09:03:51 2.390 2.390 2.390 2,800
04/10/02 09:02:27 2.390 2.390 2.390 1,000
04/10/02 09:01:03 2.390 2.390 2.390 2,900
04/10/02 08:58:12 2.390 2.390 2.390 1,800
Im Vergleich zu den Umsätzen vorher!
Ihr müßt mal auf die Seite www.investtech.com gehen.Schaut Euch mal die Kurzanalyse an.Die ist schon etwas besser geworden.(den Chart bekomme ich einfach nicht reinkopiert.wer es kann bitte mir verraten
Bis denne auf steigende Kurse Donkosak
Gruß
Viva
Das ging aber schnell
Danke
Donkosak
Danke
Donkosak
@Donkosak
Du hast Post
Gruß
Viva
Du hast Post
Gruß
Viva
Und auch heute wieder starke Umsätze! 
Gruß
Viva
Gruß
Viva
Hallo und guten Abend
Wunderlich: die Anzahl ist klein aber das Vol. , was dahintersteht
Intraday PricesDate Time High Low Close Volume
04/17/02 15:32:30 2.350 2.350 2.350 100
04/17/02 15:20:30 2.330 2.330 2.330 1,400
04/17/02 14:56:48 2.350 2.350 2.350 25,000
04/17/02 14:56:39 2.350 2.350 2.350 9,100
04/17/02 14:53:11 2.350 2.350 2.350 15,000
04/17/02 14:43:57 2.350 2.350 2.350 20,000
04/17/02 14:38:11 2.350 2.350 2.350 16,000
04/17/02 14:38:58 2.350 2.350 2.350 16,000
04/17/02 14:16:36 2.340 2.340 2.340 100
04/17/02 14:03:22 2.350 2.350 2.350 30,000
04/17/02 13:17:23 2.350 2.350 2.350 30,000
04/17/02 12:48:47 2.350 2.350 2.350 3,000
04/17/02 12:40:27 2.350 2.350 2.350 50,000
04/17/02 12:39:54 2.350 2.350 2.350 15,500
04/17/02 12:38:23 2.350 2.350 2.350 20,000
04/17/02 12:33:06 2.340 2.340 2.340 100
04/17/02 12:16:10 2.350 2.350 2.350 15,100
04/17/02 12:14:11 2.350 2.350 2.350 700
04/17/02 12:14:57 2.350 2.350 2.350 2,000
04/17/02 12:07:43 2.300 2.300 2.300 10,000
04/17/02 11:06:52 2.350 2.349 2.350 2,500
04/17/02 10:42:23 2.350 2.350 2.350 300
04/17/02 10:16:56 2.360 2.359 2.360 3,300
04/17/02 10:12:14 2.360 2.360 2.360 1,100
dazu kommt noch das der Kurs ganz streng in einem bestimmten Bereich gehalten wird(gestern bei IBPI war das ähnlich 500,000 mit einem Satz)
Na mal sehen ......
Donkosak-Grischka
Wunderlich: die Anzahl ist klein aber das Vol. , was dahintersteht
Intraday PricesDate Time High Low Close Volume
04/17/02 15:32:30 2.350 2.350 2.350 100
04/17/02 15:20:30 2.330 2.330 2.330 1,400
04/17/02 14:56:48 2.350 2.350 2.350 25,000
04/17/02 14:56:39 2.350 2.350 2.350 9,100
04/17/02 14:53:11 2.350 2.350 2.350 15,000
04/17/02 14:43:57 2.350 2.350 2.350 20,000
04/17/02 14:38:11 2.350 2.350 2.350 16,000
04/17/02 14:38:58 2.350 2.350 2.350 16,000
04/17/02 14:16:36 2.340 2.340 2.340 100
04/17/02 14:03:22 2.350 2.350 2.350 30,000
04/17/02 13:17:23 2.350 2.350 2.350 30,000
04/17/02 12:48:47 2.350 2.350 2.350 3,000
04/17/02 12:40:27 2.350 2.350 2.350 50,000
04/17/02 12:39:54 2.350 2.350 2.350 15,500
04/17/02 12:38:23 2.350 2.350 2.350 20,000
04/17/02 12:33:06 2.340 2.340 2.340 100
04/17/02 12:16:10 2.350 2.350 2.350 15,100
04/17/02 12:14:11 2.350 2.350 2.350 700
04/17/02 12:14:57 2.350 2.350 2.350 2,000
04/17/02 12:07:43 2.300 2.300 2.300 10,000
04/17/02 11:06:52 2.350 2.349 2.350 2,500
04/17/02 10:42:23 2.350 2.350 2.350 300
04/17/02 10:16:56 2.360 2.359 2.360 3,300
04/17/02 10:12:14 2.360 2.360 2.360 1,100
dazu kommt noch das der Kurs ganz streng in einem bestimmten Bereich gehalten wird(gestern bei IBPI war das ähnlich 500,000 mit einem Satz)
Na mal sehen ......
Donkosak-Grischka
4:00:14 PM Ask 2.6 900 Nasdaq NM
3:59:17 PM Bid 2.47 100 Nasdaq NM
3:58:35 PM Ask 2.58 100 Nasdaq NM
3:58:06 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:52 PM Ask 2.6 900 Nasdaq NM
3:57:52 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:46 PM Trade (at Ask) 2.6 1000 Nasdaq NM
3:57:46 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:44 PM Bid 2.48 200 Nasdaq NM
most recent back next
4:08:26 PM EDT - Friday, April 19, 2002 - data is real-time
Gruß
Viva
3:59:17 PM Bid 2.47 100 Nasdaq NM
3:58:35 PM Ask 2.58 100 Nasdaq NM
3:58:06 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:52 PM Ask 2.6 900 Nasdaq NM
3:57:52 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:46 PM Trade (at Ask) 2.6 1000 Nasdaq NM
3:57:46 PM Trade (at Ask) 2.6 100 Nasdaq NM
3:57:44 PM Bid 2.48 200 Nasdaq NM
most recent back next
4:08:26 PM EDT - Friday, April 19, 2002 - data is real-time
Gruß
Viva
--------------------------------------------------------------------------------
ViroLogic Announces First Quarter 2002 Earnings Conference Call; Tuesday, May 7, 2002 at 5:00 p.m. EDT - 2:00 p.m. PDT -
SOUTH SAN FRANCISCO, Calif., Apr 22, 2002 (BUSINESS WIRE) -- ViroLogic
(Nasdaq: VLGC) announced that it will hold a conference call on Tuesday May 7,
2002 at 5:00 p.m. EDT to discuss first quarter 2002 earnings results. The call
will be hosted by Mr. Bill Young, Chairman & CEO of Virologic, Inc.
To participate in the teleconference please call 800/388-8975 fifteen minutes
before the conference begins and ask to be connected to the ViroLogic
teleconference. International callers please dial 973/694-2225.
The call will also be webcast live at www.virologic.com. Please see web site for
details.
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized
medicine and pharmacogenomics, helping to make them realities in healthcare
around the world today. The Company discovers, develops and markets innovative
products to guide and improve treatment of serious viral diseases such as AIDS
and hepatitis. Its leading expertise in virology, molecular biology, clinical
research, engineering, information systems, and quality assurance has resulted
in technology to assess drug resistance and susceptibility in viruses that cause
these diseases, which affect millions of people worldwide.
The Company`s current products are designed to optimize HIV/AIDS treatment
regimens, providing physicians with important information to help select
appropriate drugs for their patients and leading to better outcomes and reduced
costs. These products are also being used by nearly every major pharmaceutical
company working to develop new and improved antiviral therapeutics that can be
more effective in an increasingly drug-resistant environment.
CONTACT: ViroLogic, Inc.
Karen Wilson, 650/624-4164
kwilson@virologic.com
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
PHARMACEUTICAL
ADVISORY
CONFERENCE
CALLS
SOURCE:
ViroLogic,
Inc.
ViroLogic Announces First Quarter 2002 Earnings Conference Call; Tuesday, May 7, 2002 at 5:00 p.m. EDT - 2:00 p.m. PDT -
SOUTH SAN FRANCISCO, Calif., Apr 22, 2002 (BUSINESS WIRE) -- ViroLogic
(Nasdaq: VLGC) announced that it will hold a conference call on Tuesday May 7,
2002 at 5:00 p.m. EDT to discuss first quarter 2002 earnings results. The call
will be hosted by Mr. Bill Young, Chairman & CEO of Virologic, Inc.
To participate in the teleconference please call 800/388-8975 fifteen minutes
before the conference begins and ask to be connected to the ViroLogic
teleconference. International callers please dial 973/694-2225.
The call will also be webcast live at www.virologic.com. Please see web site for
details.
About ViroLogic
ViroLogic is a biotechnology company advancing the fields of individualized
medicine and pharmacogenomics, helping to make them realities in healthcare
around the world today. The Company discovers, develops and markets innovative
products to guide and improve treatment of serious viral diseases such as AIDS
and hepatitis. Its leading expertise in virology, molecular biology, clinical
research, engineering, information systems, and quality assurance has resulted
in technology to assess drug resistance and susceptibility in viruses that cause
these diseases, which affect millions of people worldwide.
The Company`s current products are designed to optimize HIV/AIDS treatment
regimens, providing physicians with important information to help select
appropriate drugs for their patients and leading to better outcomes and reduced
costs. These products are also being used by nearly every major pharmaceutical
company working to develop new and improved antiviral therapeutics that can be
more effective in an increasingly drug-resistant environment.
CONTACT: ViroLogic, Inc.
Karen Wilson, 650/624-4164
kwilson@virologic.com
URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
PHARMACEUTICAL
ADVISORY
CONFERENCE
CALLS
SOURCE:
ViroLogic,
Inc.
Was hat das zu bedeuten am 7. Mai ? Positiv oder negativ?
Hallo und einen schönen Abend noch
Kennt Ihr das schon
Wednesday April 24, 7:32 am Eastern Time
Press Release
SOURCE: ViroLogic, Inc.
ViroLogic Announces Expanded Agreement With GlaxoSmithKline to Support Drug Development Efforts
SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - news) today announced that the Company signed an expanded agreement with GlaxoSmithKline (NYSE: GSK - news) to use ViroLogic`s proprietary HIV resistance testing technology in the Phase III clinical development of an investigational HIV protease inhibitor.
Under the terms of the agreement, GSK will use ViroLogic`s PhenoSense(TM) HIV and GeneSeq(TM) HIV assays in its Phase III clinical trials to evaluate drug resistance in over 1,000 adult and pediatric patients receiving antiretroviral drug cocktails containing the investigational compound.
``We are pleased to continue our strong relationship with GSK, a world leader in HIV therapeutics,`` said Bill Young, ViroLogic`s Chairman and Chief Executive Officer. ``This relationship highlights the integral role our multiple technologies play in HIV drug development. ViroLogic is the only company that provides a complete range of HIV resistance testing for drug development today, making us a leader in this arena. As we penetrate the earlier stages of drug discovery and development, we anticipate this part of our business will continue to grow.``
As recommended by the U.S. FDA Antiviral Drugs Advisory Committee, biopharmaceutical companies are using HIV resistance testing technology to enhance next-generation HIV drug development. There are currently16 approved HIV drugs and another 40 new drugs in the pipeline, all of which will require resistance testing for their development. ViroLogic`s patented PhenoSense technology can be applied to new HIV drug targets and is being further modified for use in vaccine research and development.
Bis denne Donkosak-Gerischka
Kennt Ihr das schon
Wednesday April 24, 7:32 am Eastern Time
Press Release
SOURCE: ViroLogic, Inc.
ViroLogic Announces Expanded Agreement With GlaxoSmithKline to Support Drug Development Efforts
SOUTH SAN FRANCISCO, Calif., April 24 /PRNewswire-FirstCall/ -- ViroLogic, Inc. (Nasdaq: VLGC - news) today announced that the Company signed an expanded agreement with GlaxoSmithKline (NYSE: GSK - news) to use ViroLogic`s proprietary HIV resistance testing technology in the Phase III clinical development of an investigational HIV protease inhibitor.
Under the terms of the agreement, GSK will use ViroLogic`s PhenoSense(TM) HIV and GeneSeq(TM) HIV assays in its Phase III clinical trials to evaluate drug resistance in over 1,000 adult and pediatric patients receiving antiretroviral drug cocktails containing the investigational compound.
``We are pleased to continue our strong relationship with GSK, a world leader in HIV therapeutics,`` said Bill Young, ViroLogic`s Chairman and Chief Executive Officer. ``This relationship highlights the integral role our multiple technologies play in HIV drug development. ViroLogic is the only company that provides a complete range of HIV resistance testing for drug development today, making us a leader in this arena. As we penetrate the earlier stages of drug discovery and development, we anticipate this part of our business will continue to grow.``
As recommended by the U.S. FDA Antiviral Drugs Advisory Committee, biopharmaceutical companies are using HIV resistance testing technology to enhance next-generation HIV drug development. There are currently16 approved HIV drugs and another 40 new drugs in the pipeline, all of which will require resistance testing for their development. ViroLogic`s patented PhenoSense technology can be applied to new HIV drug targets and is being further modified for use in vaccine research and development.
Bis denne Donkosak-Gerischka
Das müßte doch mal den Kurs beflügeln,werde nachkaufen.
Gruß
Viva
Gruß
Viva
Hallo!
Es geht weiter aufwärts momentan 2,90 Dollar in den USA,obwohl der Markt in den letzten Tagen gen Süden geht steigt Virologic.
Bin für die nächsten Tage Bullish eingestellt!
Gruß
Viva
Es geht weiter aufwärts momentan 2,90 Dollar in den USA,obwohl der Markt in den letzten Tagen gen Süden geht steigt Virologic.
Bin für die nächsten Tage Bullish eingestellt!
Gruß
Viva
Na hopla das geht aber ganz schön zur Sache
Intraday PricesDate Time High Low Close Volume
04/26/02 15:41:31 2.980 2.980 2.980 1,000
04/26/02 15:38:45 3.000 3.000 3.000 600
04/26/02 15:35:12 3.040 3.000 3.000 15,800
04/26/02 15:33:06 3.030 3.030 3.030 1,000
04/26/02 15:31:34 3.040 3.040 3.040 4,000
04/26/02 15:31:01 3.000 3.000 3.000 1,400
04/26/02 15:29:30 3.000 3.000 3.000 11,000
04/26/02 15:28:09 3.000 2.980 2.980 1,900
04/26/02 15:26:17 3.000 3.000 3.000 1,300
04/26/02 15:24:47 3.000 3.000 3.000 1,000
04/26/02 15:22:10 3.000 3.000 3.000 10,000
04/26/02 15:14:51 3.000 3.000 3.000 1,000
04/26/02 15:14:24 3.000 2.999 3.000 7,700
04/26/02 15:13:04 3.000 3.000 3.000 1,000
04/26/02 15:09:42 3.000 2.990 3.000 4,200
04/26/02 15:08:39 3.000 3.000 3.000 2,000
04/26/02 15:05:12 2.990 2.990 2.990 900
04/26/02 15:05:58 2.990 2.990 2.990 100
04/26/02 15:04:08 3.000 3.000 3.000 4,000
04/26/02 15:01:36 2.990 2.990 2.990 2,700
04/26/02 14:58:04 2.990 2.980 2.990 1,200
04/26/02 14:56:09 2.969 2.969 2.969 500
04/26/02 14:49:08 2.960 2.960 2.960 1,200
04/26/02 14:44:25 2.960 2.900 2.900 10,400
04/26/02 14:42:19 2.950 2.910 2.950 15,000
Das kann sich sehen lassen.Bis denn Donkoska-Grischka
Intraday PricesDate Time High Low Close Volume
04/26/02 15:41:31 2.980 2.980 2.980 1,000
04/26/02 15:38:45 3.000 3.000 3.000 600
04/26/02 15:35:12 3.040 3.000 3.000 15,800
04/26/02 15:33:06 3.030 3.030 3.030 1,000
04/26/02 15:31:34 3.040 3.040 3.040 4,000
04/26/02 15:31:01 3.000 3.000 3.000 1,400
04/26/02 15:29:30 3.000 3.000 3.000 11,000
04/26/02 15:28:09 3.000 2.980 2.980 1,900
04/26/02 15:26:17 3.000 3.000 3.000 1,300
04/26/02 15:24:47 3.000 3.000 3.000 1,000
04/26/02 15:22:10 3.000 3.000 3.000 10,000
04/26/02 15:14:51 3.000 3.000 3.000 1,000
04/26/02 15:14:24 3.000 2.999 3.000 7,700
04/26/02 15:13:04 3.000 3.000 3.000 1,000
04/26/02 15:09:42 3.000 2.990 3.000 4,200
04/26/02 15:08:39 3.000 3.000 3.000 2,000
04/26/02 15:05:12 2.990 2.990 2.990 900
04/26/02 15:05:58 2.990 2.990 2.990 100
04/26/02 15:04:08 3.000 3.000 3.000 4,000
04/26/02 15:01:36 2.990 2.990 2.990 2,700
04/26/02 14:58:04 2.990 2.980 2.990 1,200
04/26/02 14:56:09 2.969 2.969 2.969 500
04/26/02 14:49:08 2.960 2.960 2.960 1,200
04/26/02 14:44:25 2.960 2.900 2.900 10,400
04/26/02 14:42:19 2.950 2.910 2.950 15,000
Das kann sich sehen lassen.Bis denn Donkoska-Grischka
Latest News
--------------------------------------------------------------------------------
ViroLogic Launches First Viral Fitness Assay for HIV Patient Testing New Test Measures HIV `Replication Capacity` to Help Guide Treatment
SOUTH SAN FRANCISCO, Calif., Jun 3, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today announced the launch of the first-ever
commercial laboratory test to evaluate the "replication capacity" (or viral
"fitness") of HIV. ViroLogic`s new Replication Capacity (RC) assay measures the
ability of a patient`s virus to make copies of itself and is designed to provide
useful additional information to physicians to select optimal antiretroviral
therapy cocktails for their patients.
The RC test will be provided in combination with ViroLogic`s PhenoSense(TM) HIV
and PhenoSense GT(TM) drug resistance tests at no additional charge. With the
launch of the RC assay, ViroLogic now offers four products for patient testing
and seven for biopharmaceutical drug development.
"The addition of replication capacity information to our PhenoSense assays will
give ViroLogic another competitive edge in the resistance testing market," said
Bill Young, Chairman and CEO of ViroLogic. "We expect it to help drive further
growth of our patient testing business just as we experienced with the addition
of genotypic information on our PhenoSense assay to create PhenoSense GT. As
more physicians experience the benefits of having this value-added information,
the more likely they are to convert their business to ViroLogic`s tests. We plan
to add more information like this to our assays over time to maintain our
competitive advantage and drive continually greater use and adoption of our
product line."
Recent research studies suggest that replication capacity data, in combination
with drug resistance information, viral load and CD4 count, may allow for a more
informed prediction of HIV disease progression. For example, using ViroLogic`s
RC assay, physicians can identify situations in which the replication capacity
of a patient`s virus is impaired, which often occurs when the virus has
extensively mutated to become resistant to an antiretroviral drug regimen. In
these cases, even though the antiretroviral drugs are no longer fully
controlling replication of the virus, a physician may choose to maintain the
regimen in order to keep the mutated, less "fit" strain of HIV in the patient`s
body, especially if the patient has few or no other treatment options.
"Successfully treating HIV has become increasingly complex, and having more
information about the patient`s individual virus may help in making better
treatment decisions," said Charles Hicks, M.D., Associate Clinical Professor of
Medicine, Duke University Medical Center. "As HIV drug resistance and treatment
failures continue to rise, the role of the replication capacity assay in
clinical decision making may prove to be of considerable value by providing
supplemental individualized patient information."
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine and
pharmacogenomics by discovering, developing and marketing innovative products to
guide and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company`s products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company`s technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines
targeted at emerging drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the Company`s agreements with third parties. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, those
related to performance or non-performance of the Company and those it contracts
with under the Company`s third-party agreements, whether ViroLogic`s products
will achieve market acceptance, whether payers will authorize reimbursement for
our products, whether we will be able to expand our sales and marketing
capabilities, whether the FDA or any other agency will decide to further
regulate our products or services, whether we will encounter problems or delays
in automating our process, whether we will successfully introduce new products
using our PhenoSense technology, whether intellectual property underlying our
technology is adequate, whether we are able to build brand loyalty, whether we
will be able to raise sufficient capital and other risks and uncertainties
detailed from time to time in our reports to the Securities and Exchange
Commission, including our report on Form 10-K for the year ended December 31,
2001.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X51701816
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
(VLGC)
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
KEYWORD: California
INDUSTRY KEYWORD: BIO
HEA
SUBJECT CODE: PDT
--------------------------------------------------------------------------------
ViroLogic Launches First Viral Fitness Assay for HIV Patient Testing New Test Measures HIV `Replication Capacity` to Help Guide Treatment
SOUTH SAN FRANCISCO, Calif., Jun 3, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) today announced the launch of the first-ever
commercial laboratory test to evaluate the "replication capacity" (or viral
"fitness") of HIV. ViroLogic`s new Replication Capacity (RC) assay measures the
ability of a patient`s virus to make copies of itself and is designed to provide
useful additional information to physicians to select optimal antiretroviral
therapy cocktails for their patients.
The RC test will be provided in combination with ViroLogic`s PhenoSense(TM) HIV
and PhenoSense GT(TM) drug resistance tests at no additional charge. With the
launch of the RC assay, ViroLogic now offers four products for patient testing
and seven for biopharmaceutical drug development.
"The addition of replication capacity information to our PhenoSense assays will
give ViroLogic another competitive edge in the resistance testing market," said
Bill Young, Chairman and CEO of ViroLogic. "We expect it to help drive further
growth of our patient testing business just as we experienced with the addition
of genotypic information on our PhenoSense assay to create PhenoSense GT. As
more physicians experience the benefits of having this value-added information,
the more likely they are to convert their business to ViroLogic`s tests. We plan
to add more information like this to our assays over time to maintain our
competitive advantage and drive continually greater use and adoption of our
product line."
Recent research studies suggest that replication capacity data, in combination
with drug resistance information, viral load and CD4 count, may allow for a more
informed prediction of HIV disease progression. For example, using ViroLogic`s
RC assay, physicians can identify situations in which the replication capacity
of a patient`s virus is impaired, which often occurs when the virus has
extensively mutated to become resistant to an antiretroviral drug regimen. In
these cases, even though the antiretroviral drugs are no longer fully
controlling replication of the virus, a physician may choose to maintain the
regimen in order to keep the mutated, less "fit" strain of HIV in the patient`s
body, especially if the patient has few or no other treatment options.
"Successfully treating HIV has become increasingly complex, and having more
information about the patient`s individual virus may help in making better
treatment decisions," said Charles Hicks, M.D., Associate Clinical Professor of
Medicine, Duke University Medical Center. "As HIV drug resistance and treatment
failures continue to rise, the role of the replication capacity assay in
clinical decision making may prove to be of considerable value by providing
supplemental individualized patient information."
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine and
pharmacogenomics by discovering, developing and marketing innovative products to
guide and improve treatment of serious viral diseases such as AIDS and
hepatitis. The Company`s products are designed to help doctors optimize
treatment regimens for their patients that lead to better outcomes and reduced
costs. The Company`s technology is also being used by numerous biopharmaceutical
companies to develop new and improved antiviral therapeutics and vaccines
targeted at emerging drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the Company`s agreements with third parties. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, those
related to performance or non-performance of the Company and those it contracts
with under the Company`s third-party agreements, whether ViroLogic`s products
will achieve market acceptance, whether payers will authorize reimbursement for
our products, whether we will be able to expand our sales and marketing
capabilities, whether the FDA or any other agency will decide to further
regulate our products or services, whether we will encounter problems or delays
in automating our process, whether we will successfully introduce new products
using our PhenoSense technology, whether intellectual property underlying our
technology is adequate, whether we are able to build brand loyalty, whether we
will be able to raise sufficient capital and other risks and uncertainties
detailed from time to time in our reports to the Securities and Exchange
Commission, including our report on Form 10-K for the year ended December 31,
2001.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X51701816
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
(VLGC)
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
KEYWORD: California
INDUSTRY KEYWORD: BIO
HEA
SUBJECT CODE: PDT
Latest News
--------------------------------------------------------------------------------
ViroLogic Announces Expanded Agreement With Pfizer to Support New HIV Drug Discovery and Development Efforts
SOUTH SAN FRANCISCO, Calif., Jun 18, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed an
expanded agreement with Pfizer Inc (NYSE: PFE) to use ViroLogic`s novel HIV
resistance testing technology for Pfizer`s HIV drug discovery and development
programs. The new agreement covers work performed for all of Pfizer`s Global
Research and Development sites worldwide.
ViroLogic has developed technologies to assess drug resistance among a number of
antiretroviral therapies in both preclinical and clinical studies including
PhenoSense(TM) HIV, GeneSeq(TM), PhenoSenseGT(TM), PhenoSense HIV Entry(TM) and
PhenoScreen(TM).
"This expanded agreement highlights how ViroLogic can serve as the drug
resistance partner of choice to address a multitude of needs for the discovery
and development of new HIV therapeutics -- from new drug candidate screening and
preclinical research to late-stage clinical trials," said Bill Young,
ViroLogic`s Chairman and Chief Executive Officer.
As recommended by the U.S. FDA Antiviral Drugs Advisory Committee,
biopharmaceutical companies are using HIV resistance testing technology to
enhance next-generation HIV drug development. The industry currently has 16
approved HIV drugs and another 40 new drugs in the pipeline, all of which will
require resistance testing for their development. ViroLogic`s patented
technology can be applied to new HIV drug targets and is being further modified
for use in vaccine research and development.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis. The Company`s
products are designed to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs. The Company`s
technology is also being used by numerous biopharmaceutical companies to develop
new and improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the Company`s agreements with third parties. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, those
related to performance or non-performance of the Company and those it contracts
with under the Company`s third-party agreements, whether ViroLogic`s products
will achieve market acceptance, whether payers will authorize reimbursement for
our products, whether we will be able to expand our sales and marketing
capabilities, whether the FDA or any other agency will decide to further
regulate our products or services, whether we will encounter problems or delays
in automating our process, whether we will successfully introduce new products
using our PhenoSense technology, whether intellectual property underlying our
technology is adequate, whether we are able to build brand loyalty, whether we
will be able to raise sufficient capital and other risks and uncertainties
detailed from time to time in our reports to the Securities and Exchange
Commission, including our report on Form 10-K for the year ended December 31,
2001.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X27666514
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
URL: http://www.virologic.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
KEYWORD: California
INDUSTRY KEYWORD: BIO
HEA
MTC
SUBJECT CODE: CON
--------------------------------------------------------------------------------
ViroLogic Announces Expanded Agreement With Pfizer to Support New HIV Drug Discovery and Development Efforts
SOUTH SAN FRANCISCO, Calif., Jun 18, 2002 /PRNewswire-FirstCall via COMTEX/ --
ViroLogic, Inc. (Nasdaq: VLGC) announced today that the Company has signed an
expanded agreement with Pfizer Inc (NYSE: PFE) to use ViroLogic`s novel HIV
resistance testing technology for Pfizer`s HIV drug discovery and development
programs. The new agreement covers work performed for all of Pfizer`s Global
Research and Development sites worldwide.
ViroLogic has developed technologies to assess drug resistance among a number of
antiretroviral therapies in both preclinical and clinical studies including
PhenoSense(TM) HIV, GeneSeq(TM), PhenoSenseGT(TM), PhenoSense HIV Entry(TM) and
PhenoScreen(TM).
"This expanded agreement highlights how ViroLogic can serve as the drug
resistance partner of choice to address a multitude of needs for the discovery
and development of new HIV therapeutics -- from new drug candidate screening and
preclinical research to late-stage clinical trials," said Bill Young,
ViroLogic`s Chairman and Chief Executive Officer.
As recommended by the U.S. FDA Antiviral Drugs Advisory Committee,
biopharmaceutical companies are using HIV resistance testing technology to
enhance next-generation HIV drug development. The industry currently has 16
approved HIV drugs and another 40 new drugs in the pipeline, all of which will
require resistance testing for their development. ViroLogic`s patented
technology can be applied to new HIV drug targets and is being further modified
for use in vaccine research and development.
About ViroLogic
ViroLogic is a biotechnology company advancing individualized medicine by
discovering, developing and marketing innovative products to guide and improve
treatment of serious viral diseases such as AIDS and hepatitis. The Company`s
products are designed to help doctors optimize treatment regimens for their
patients that lead to better outcomes and reduced costs. The Company`s
technology is also being used by numerous biopharmaceutical companies to develop
new and improved antiviral therapeutics and vaccines targeted at emerging
drug-resistant viruses.
Certain statements in this press release are forward-looking, including
statements relating to the Company`s agreements with third parties. These
forward-looking statements are subject to risks and uncertainties and other
factors, which may cause actual results to differ materially from the
anticipated results or other expectations expressed in such forward-looking
statements. These risks and uncertainties include, but are not limited to, those
related to performance or non-performance of the Company and those it contracts
with under the Company`s third-party agreements, whether ViroLogic`s products
will achieve market acceptance, whether payers will authorize reimbursement for
our products, whether we will be able to expand our sales and marketing
capabilities, whether the FDA or any other agency will decide to further
regulate our products or services, whether we will encounter problems or delays
in automating our process, whether we will successfully introduce new products
using our PhenoSense technology, whether intellectual property underlying our
technology is adequate, whether we are able to build brand loyalty, whether we
will be able to raise sufficient capital and other risks and uncertainties
detailed from time to time in our reports to the Securities and Exchange
Commission, including our report on Form 10-K for the year ended December 31,
2001.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X27666514
SOURCE ViroLogic, Inc.
CONTACT: Karen Wilson, CFO of ViroLogic, Inc., +1-650-624-4164, or
kwilson@virologic.com
URL: http://www.virologic.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
KEYWORD: California
INDUSTRY KEYWORD: BIO
HEA
MTC
SUBJECT CODE: CON
Hallo Ihr da draussen
Na ist man mal zwei Wochen im Urlaub und dann kommt so eine Nachricht mit Pfizer
Aber was geschah danach wir bekommen nach so einer "geilen" News satte 1% plus(satte 1 % Pluuus)
Inspire die gestern irgendwelche Ph 2/3 News für Augentropfen bringen, und jetzt kommts " gegen trockene Augen"(da gibt es auf dem Markt ca.100 Produkte) steigen um 100% Pluus
Da stimmt doch an der Börse gewaltig was nicht mehr.Mit Augentropfen die wieder sehend machen kann man solch eine Steigerung rechtfertigen.
Egal wir werden weiter hoffen
bis denne Donkosak
PS: gerade sind 800.000 über die Bühne gelaufen
Na ist man mal zwei Wochen im Urlaub und dann kommt so eine Nachricht mit Pfizer
Aber was geschah danach wir bekommen nach so einer "geilen" News satte 1% plus(satte 1 % Pluuus)
Inspire die gestern irgendwelche Ph 2/3 News für Augentropfen bringen, und jetzt kommts " gegen trockene Augen"(da gibt es auf dem Markt ca.100 Produkte) steigen um 100% Pluus
Da stimmt doch an der Börse gewaltig was nicht mehr.Mit Augentropfen die wieder sehend machen kann man solch eine Steigerung rechtfertigen.
Egal wir werden weiter hoffen
bis denne Donkosak
PS: gerade sind 800.000 über die Bühne gelaufen
Hallo!
Es ist sehr still in diesem Forum geworden.
Die Aktie hält sich (noch) phantastisch.
Wie seht ihr die weiteren Aussichten? Wie wird es weitergehen?
Gruss
b742418
Es ist sehr still in diesem Forum geworden.
Die Aktie hält sich (noch) phantastisch.
Wie seht ihr die weiteren Aussichten? Wie wird es weitergehen?
Gruss
b742418
Ich rate eher dazu Kurse über 3 Dollar zum Ausstieg nützen.
Wenn mal ein großer Rausgeht dann kanns schnell gehen!
Ich selber bin im Mai mit ca 3,20 Dollar raus
mfg hubi3
Wenn mal ein großer Rausgeht dann kanns schnell gehen!
Ich selber bin im Mai mit ca 3,20 Dollar raus
mfg hubi3
@hubi
Warum raus aus Virologic?
Der wert hat sich doch gegeüber dem Gesamtmarkt super gehalten.
Und gerade Du warst doch jemand der immer nur positiv über Virologic geschrieben hat.
Gruß
Viva
Warum raus aus Virologic?
Der wert hat sich doch gegeüber dem Gesamtmarkt super gehalten.
Und gerade Du warst doch jemand der immer nur positiv über Virologic geschrieben hat.
Gruß
Viva
07/22/2002 (08:01 ET) ViroLogic Announces Second Quarter 2002 Earnings Conference Call; Thursday, August 1, 2002 at 5:00 p.m. EDT, 2:00 p.m. PDT - Business Wire
07/19/2002 (10:57 ET) Immune Network enters research agreement with ViroLogic to evaluate anti-HIV antibody - Datamonitor
07/18/2002 (15:01 ET) IMMUNE NETWORK LTD: VIROLOGIC INC - Immune Network Enters Research Evaluation Agreement With - ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Market News Publishing
07/18/2002 (15:00 ET) Immune Network Enters Research Evaluation Agreement with ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Canadian Corporate News
07/18/2002 (14:11 ET) Immune Network Enters Research Evaluation Agreement with ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Business Wire
JS200
07/19/2002 (10:57 ET) Immune Network enters research agreement with ViroLogic to evaluate anti-HIV antibody - Datamonitor
07/18/2002 (15:01 ET) IMMUNE NETWORK LTD: VIROLOGIC INC - Immune Network Enters Research Evaluation Agreement With - ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Market News Publishing
07/18/2002 (15:00 ET) Immune Network Enters Research Evaluation Agreement with ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Canadian Corporate News
07/18/2002 (14:11 ET) Immune Network Enters Research Evaluation Agreement with ViroLogic to Evaluate Anti-HIV Antibody hNM01 - Business Wire
JS200
Bei dieser Art Aktien (High Risk) stehen bei mir die Charttechnischen kritierien im vordergrund.
Es muß nur irgend ein Biotechfonds aufgelöst werden und eine so derart "enge"´Aktie fällt ins bodenlose.
Fundamentaldaten sind bei dieser Gesamtmarktverfassung egal!
Es muß nur irgend ein Biotechfonds aufgelöst werden und eine so derart "enge"´Aktie fällt ins bodenlose.
Fundamentaldaten sind bei dieser Gesamtmarktverfassung egal!
So jetzt ist es passiert 1,61 Dollar .
Wer auf mich gehört hat hat viel Geld gspart
Mehr Infos für die Zukunft. hupi99@yahoo kontaktieren
mfg hubi3
Wer auf mich gehört hat hat viel Geld gspart
Mehr Infos für die Zukunft. hupi99@yahoo kontaktieren
mfg hubi3
Hallo!
Kann das vielleicht jemand in groben Zügen übersetzen?
Vielen Dank!
Gruss
************************************************************
ViroLogic, Inc. today reported financial results for the second quarter ended June 30, 2002.
The Company reported revenue of $6.7 million for the second quarter, up 40 percent over revenue of $4.8 million for the same period in 2001.
"I am pleased with our continued revenue growth during the quarter, in particular with our patient testing revenue, which grew by approximately 30 percent over the first quarter and increased 60 percent over the same quarter of last year, driven by the continued success of PhenoSense GT," said Bill Young, CEO and Chairman of ViroLogic. "We also significantly improved our gross margins and managed operating costs, enabling us to achieve a lower-than-expected net loss for the quarter. However, due to delays by pharmaceutical companies in the start of clinical projects and the growth in patient testing business projected for the remainder of the year, we are adjusting our full-year 2002 revenue forecast to be in the range of $28 to $32 million. This represents a significant increase over full-year 2001 revenue of $18.3 million. We now anticipate breakeven in the second half of 2003. Given this later break-even point, we are aggressively managing our costs and focusing our resources on revenue-generating activities."
Gross margin was 42 percent in the second quarter of 2002 compared to 38 percent reported last quarter and 31 percent in the second quarter of 2001. Operating costs and expenses for the second quarter were $12.2 million, compared to $10.9 million for the same period in 2001. The increase primarily reflects the higher testing volume, growth of the sales force and sales and marketing activities to support new product launches. Net loss was $5.5 million, or $0.22 per share, compared to a net loss of $5.9 million, or $0.29 per share, for the same period in 2001. In the second quarter of 2002, the Company recorded a dividend to preferred stockholders of $0.3 million resulting in net loss applicable to common stockholders of $0.24 per common share.
The Company had $8.9 million of cash, restricted cash and short-term investments as of June 30, 2002. In the second half of 2002, the Company will also be receiving an additional $2 million as part of a building lease assignment for excess space.
Recent Highlights -- Launched first and only measurement of "replication capacity" of HIV (also known as viral fitness) that quantifies the ability of a patient``s virus to make copies of itself and is designed to provide useful additional information to physicians for the selection of optimal antiretroviral therapy cocktails for their patients; -- Expanded agreement with Pfizer to use ViroLogic``s assays to assess resistance among three antiretroviral drug classes in preclinical and clinical studies; -- Announced new drug development agreements with Progenics and Immune Networks; -- Expanded Medicaid coverage of resistance testing to 46 states and the District of Columbia; the remaining four states have pending reimbursement coverage policies; -- Presented 16 studies using ViroLogic``s technology at 11th International HIV Drug Resistance Workshop in Seville, Spain, several highlighting the clinical role of replication capacity; -- Presented 11 studies using ViroLogic``s technology at 14th International AIDS Conference in Barcelona. One of the most highly attended scientific sessions was "New Drugs for New Targets," which featured talks about progress in the development of novel integrase inhibitors, CCR5 chemokine receptor inhibitors, fusion inhibitors, humanized antibody attachment inhibitors and CXCR4 inhibitors. Presenters specifically included ViroLogic data or technology as key components of their drug development activities; -- Published research in July 7 issue of the Journal of the American Medical Association (JAMA) using ViroLogic``s PhenoSense assay that indicated resistance testing should play a greater role in guiding treatment for newly infected HIV patients. Conference Call Details
ViroLogic will hold a conference call today at 5:00 p.m. EDT to discuss second quarter 2002 earnings results. To participate in the teleconference please call 800-360-9865 fifteen minutes before the conference begins and ask to be connected to the ViroLogic teleconference. International callers please dial 973-694-6836. The call will also be webcast live at http://www.virologic.com/. Please see web site for details.
Kann das vielleicht jemand in groben Zügen übersetzen?
Vielen Dank!
Gruss
************************************************************
ViroLogic, Inc. today reported financial results for the second quarter ended June 30, 2002.
The Company reported revenue of $6.7 million for the second quarter, up 40 percent over revenue of $4.8 million for the same period in 2001.
"I am pleased with our continued revenue growth during the quarter, in particular with our patient testing revenue, which grew by approximately 30 percent over the first quarter and increased 60 percent over the same quarter of last year, driven by the continued success of PhenoSense GT," said Bill Young, CEO and Chairman of ViroLogic. "We also significantly improved our gross margins and managed operating costs, enabling us to achieve a lower-than-expected net loss for the quarter. However, due to delays by pharmaceutical companies in the start of clinical projects and the growth in patient testing business projected for the remainder of the year, we are adjusting our full-year 2002 revenue forecast to be in the range of $28 to $32 million. This represents a significant increase over full-year 2001 revenue of $18.3 million. We now anticipate breakeven in the second half of 2003. Given this later break-even point, we are aggressively managing our costs and focusing our resources on revenue-generating activities."
Gross margin was 42 percent in the second quarter of 2002 compared to 38 percent reported last quarter and 31 percent in the second quarter of 2001. Operating costs and expenses for the second quarter were $12.2 million, compared to $10.9 million for the same period in 2001. The increase primarily reflects the higher testing volume, growth of the sales force and sales and marketing activities to support new product launches. Net loss was $5.5 million, or $0.22 per share, compared to a net loss of $5.9 million, or $0.29 per share, for the same period in 2001. In the second quarter of 2002, the Company recorded a dividend to preferred stockholders of $0.3 million resulting in net loss applicable to common stockholders of $0.24 per common share.
The Company had $8.9 million of cash, restricted cash and short-term investments as of June 30, 2002. In the second half of 2002, the Company will also be receiving an additional $2 million as part of a building lease assignment for excess space.
Recent Highlights -- Launched first and only measurement of "replication capacity" of HIV (also known as viral fitness) that quantifies the ability of a patient``s virus to make copies of itself and is designed to provide useful additional information to physicians for the selection of optimal antiretroviral therapy cocktails for their patients; -- Expanded agreement with Pfizer to use ViroLogic``s assays to assess resistance among three antiretroviral drug classes in preclinical and clinical studies; -- Announced new drug development agreements with Progenics and Immune Networks; -- Expanded Medicaid coverage of resistance testing to 46 states and the District of Columbia; the remaining four states have pending reimbursement coverage policies; -- Presented 16 studies using ViroLogic``s technology at 11th International HIV Drug Resistance Workshop in Seville, Spain, several highlighting the clinical role of replication capacity; -- Presented 11 studies using ViroLogic``s technology at 14th International AIDS Conference in Barcelona. One of the most highly attended scientific sessions was "New Drugs for New Targets," which featured talks about progress in the development of novel integrase inhibitors, CCR5 chemokine receptor inhibitors, fusion inhibitors, humanized antibody attachment inhibitors and CXCR4 inhibitors. Presenters specifically included ViroLogic data or technology as key components of their drug development activities; -- Published research in July 7 issue of the Journal of the American Medical Association (JAMA) using ViroLogic``s PhenoSense assay that indicated resistance testing should play a greater role in guiding treatment for newly infected HIV patients. Conference Call Details
ViroLogic will hold a conference call today at 5:00 p.m. EDT to discuss second quarter 2002 earnings results. To participate in the teleconference please call 800-360-9865 fifteen minutes before the conference begins and ask to be connected to the ViroLogic teleconference. International callers please dial 973-694-6836. The call will also be webcast live at http://www.virologic.com/. Please see web site for details.
Na Du bist vielleicht ne Blase "Hubi"
Wann gab es denn in der letzten Zeit(seit Deiner Mail) Kurse über 3
Dann hättest Du schon Kurse über 2,3 für den Ausstieg nennen müssen.
Bis denne Donkosak
Wann gab es denn in der letzten Zeit(seit Deiner Mail) Kurse über 3
Dann hättest Du schon Kurse über 2,3 für den Ausstieg nennen müssen.
Bis denne Donkosak
Nachtrag
Der "Große" der ausgestiegen ist hat dann sage und schreibe am Freitag für den Kurssturz nur 138.000 benötigt
Der "Große" der ausgestiegen ist hat dann sage und schreibe am Freitag für den Kurssturz nur 138.000 benötigt
Nachtrag 2
Übrigens "ich will keine Daten haben"áber im Monat Mai hatten wir keine 3,2 gesehen oder doch
Donkosak
Übrigens "ich will keine Daten haben"áber im Monat Mai hatten wir keine 3,2 gesehen oder doch
Donkosak
05.08.2002
ViroLogic "buy"
CIBC World Markets
Rating-Update:
Die Analysten vom Investmenthaus CIBC World Markets stufen die Aktie von ViroLogic (WKN 936848) von "strong buy" auf "buy" zurück.
ViroLogic "buy"
CIBC World Markets
Rating-Update:
Die Analysten vom Investmenthaus CIBC World Markets stufen die Aktie von ViroLogic (WKN 936848) von "strong buy" auf "buy" zurück.
wie einer AG der boden unter den füßen wegbrechen kann von ängstlichen aktionären ist dieser unsinnige verkauf und panik der anleger.nichts spricht gegen VLGC 40% umsatzsteierung , zur zeit kann jeder die kasse von VLGC kaufen mit nur einer aktie die er erwirbt.bb-biotech hält z.b.1% von VLGC und sieht keinen grund in dieser panik sich von diesem investment zu trennen.
grüße t.1
grüße t.1
Virologic ist ein solides Investment im Biotechbereich.
Im nächsten Jahr werden Profite geschrieben, was sehr konservativ klingt, den auf der Aids-Konferenz in Barcelona
wurden einige Verträge neu abgeschlossen. Zur Zeit wird der Kurs manipuliert durch schlechte Stimmungsmacher in Amerika.
Mit dieser Aktie ist ein Gewinn von 1000% zu machen
in den nächsten 5 Jahren. Zur Zeit bekommt man diese Aktie zu einem Vorzugspreis von 1 Dollar. Investmenthäuser werden
in den nächsten Monaten einige Stücke einsammeln um die Übernahme durch einen Pharmakonzern vorzubereiten.
Ein fairer Preis von 10 Dollar ist wahrscheinlich als Übernahmeangebot. Weitere unberücksichtigte Fakten werden
verschleiert, um die grossen Haie zu einem Vorzugspreis
einsteigen zu lassen. Es ist logisch das beinem Goldrausch
(Aids) derjenige profitiert der Hacke und Spaten(Testsystem) liefert und nicht hunderte Millionen Dollar verbrennt.Die Zeit ist reif paradoxe Investmentstrategien zu entwickeln und sich von seinem Bauchgefühl leiten zu lassen.
Im nächsten Jahr werden Profite geschrieben, was sehr konservativ klingt, den auf der Aids-Konferenz in Barcelona
wurden einige Verträge neu abgeschlossen. Zur Zeit wird der Kurs manipuliert durch schlechte Stimmungsmacher in Amerika.
Mit dieser Aktie ist ein Gewinn von 1000% zu machen
in den nächsten 5 Jahren. Zur Zeit bekommt man diese Aktie zu einem Vorzugspreis von 1 Dollar. Investmenthäuser werden
in den nächsten Monaten einige Stücke einsammeln um die Übernahme durch einen Pharmakonzern vorzubereiten.
Ein fairer Preis von 10 Dollar ist wahrscheinlich als Übernahmeangebot. Weitere unberücksichtigte Fakten werden
verschleiert, um die grossen Haie zu einem Vorzugspreis
einsteigen zu lassen. Es ist logisch das beinem Goldrausch
(Aids) derjenige profitiert der Hacke und Spaten(Testsystem) liefert und nicht hunderte Millionen Dollar verbrennt.Die Zeit ist reif paradoxe Investmentstrategien zu entwickeln und sich von seinem Bauchgefühl leiten zu lassen.
und wie erklärst du dir diesen absturz?
Der Absturz ist im Zuge des Spiels das man Boerse nennt entstanden. Halten die Anleger den nervlichen Druck stand
oder verlieren Sie ihr letztes Hemd.
oder verlieren Sie ihr letztes Hemd.
@derprofitgierige
habe mit deinem inhalt die gleiche antwort erhalten.bb-biotech glaubt fest an virologic,hält übernahme in kurtzer zeit für sehr wahrscheinlich und meint in nächster zeit kommt eine wichtige news von denen.
grüße t.1
das ist eine super gelegenheit...bei matrix pharma ging es geauso ab.
habe mit deinem inhalt die gleiche antwort erhalten.bb-biotech glaubt fest an virologic,hält übernahme in kurtzer zeit für sehr wahrscheinlich und meint in nächster zeit kommt eine wichtige news von denen.
grüße t.1
das ist eine super gelegenheit...bei matrix pharma ging es geauso ab.
schade dass heute Feiertag in den USA ist !!
die Rally hat somit einen Dämpfer von eimem Tag)!! morgen gehts weiter
!!die Rally hat somit einen Dämpfer von eimem Tag
)!! morgen gehts weiter
Dummschwätzender Volltrottel...
wirst schon noch sehen mein Freund...)!!
obwohl dass das im Moment eine Bodenbildung ist siehst du bestimmt nicht!!
du bist bestimmt so einer wo fett in Dax-Calls investiert ist und denkt sag mal soweit kann es doch nicht nach unten gehen dass ist alles zuviel...Volltrottel!!
)!!obwohl dass das im Moment eine Bodenbildung ist siehst du bestimmt nicht!!
du bist bestimmt so einer wo fett in Dax-Calls investiert ist und denkt sag mal soweit kann es doch nicht nach unten gehen dass ist alles zuviel...Volltrottel!!
Aug. 15, 2002 849,357 116,038 7.32
Jul. 15, 2002 885,027 193,774 4.57
Jun. 14, 2002 769,325 67,856 11.34
zahlen bei nasdaq.com unter vlgc short positionen.da versprechen sich einige einen dicken gewinn.
Jul. 15, 2002 885,027 193,774 4.57
Jun. 14, 2002 769,325 67,856 11.34
zahlen bei nasdaq.com unter vlgc short positionen.da versprechen sich einige einen dicken gewinn.
0,85€
Damit ist wohl klar, wer der Volltrottel ist...
Ohne den Kollegen recoil in Schutz nehmen zu wollen.
Damit ist wohl klar, wer der Volltrottel ist...
Ohne den Kollegen recoil in Schutz nehmen zu wollen.
0,81€
Hurricanfighterplane4
über 18% NACH OBEN NUN MUß ICH ÜBER DICH KRÄFTIG LACHEN...
über 18% NACH OBEN NUN MUß ICH ÜBER DICH KRÄFTIG LACHEN...
jaaaaaaaa der Boden war da!!! jetzt kennt VIRO nur noch 1 Richtung!!
Umsätze riesig jetzt auch in Deutschland!!
VIRO weiter so!!!!
Umsätze riesig jetzt auch in Deutschland!!
VIRO weiter so!!!!
Gab es bei Virologic irgendeine gute News oder warum steigt Sie gegen den Markt?
Gruß
Viva
Gruß
Viva
nennt mich Warren Buffet !!!
!!! 
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 200 | ||
| 184 | ||
| 132 | ||
| 70 | ||
| 29 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 26 | ||
| 26 |
| Wertpapier | Beiträge | |
|---|---|---|
| 26 | ||
| 25 | ||
| 25 | ||
| 23 | ||
| 23 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 20 | ||
| 20 |
